MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Botulinum toxin: Clinical applications: other"

  • 2019 International Congress

    The effect of Guided Self-rehabilitation Contracts combined with simultaneous injections of abobotulinumtoxinA into upper and lower limbs on voluntary movements in adults with spastic hemiparesis

    J-M. Gracies, G. Francisco, R. Jech, S. Khatkova, C. Rios, P. Maisonobe (Créteil, France)

    Objective: To report primary outcomes from ENGAGE, an international phase 3b/4, prospective, single-arm, open-label study (NCT02969356). Background: ENGAGE assessed effects of Guided Self-rehabilitation Contracts (GSC)…
  • 2019 International Congress

    IncobotulinumtoxinA is effective, long lasting and well tolerated treatment of hemifacial spasm

    S. Ochudlo, A. Krzak-Kubica, J. Gawryluk (Katowice, Poland)

    Objective: Hemifacial spasm (HFS) is a common movement disorder characterized by involuntary contractions of the muscles innervated by facial nerve. Background: To evaluate the effect…
  • 2019 International Congress

    Holmes Tremor : contribution of Botulinum toxin injection strategy guided by electromyographic (EMG) polygraphic recording

    F. Jomier, Y. Beaugendre Ahmar, E. Apartis, D. Grabli (Paris, France)

    Objective: To show that botulinum toxin injections guided by EMG polygraphic recording is effective to improve  proximal upper limbs tremor. Background: Holmes tremor is highly disabling,…
  • 2018 International Congress

    The comparison of the clinical characteristics and treatment outcomes between non-troublesome and troublesome hemifacial spasm in Thai patients

    Y. Pitakpatapee, A. Suengtaworn, P. Soontrapa, P. Srivanitchapoom (Bangkok, Thailand)

    Objective: To compare the clinical characteristics and treatment outcomes after injection of botulinum neurotoxin (BoNT) type A between non-troublesome and troublesome hemifacial spasm (HFS) in…
  • 2018 International Congress

    Economics of Botulinum Toxin Therapy: Influence of the AbobotulinumtoxinA Package Size on the Costs of Botulinum Toxin Therapy

    F. Adib Saberi, D. Dressler (Hamburg, Germany)

    Objective: To explore whether more differentiated package sizes allow for more economic use of Dysport® in a large neurological botulinum toxin (BT) outpatient clinic (>9000…
  • 2018 International Congress

    Botulinum toxin injection for Pisa syndrome in Parkinson’s disease

    CA. Artusi, M. Zibetti, P. Barbero, M. Busso, S. Bortolani, S. De Mercanti, P. Arnoffi, M. Fabbri, A. Merola, L. Lopiano (Torino, Italy)

    Objective: We sought to assess the clinical efficacy of Botulinum toxin (BoNT) injection for Pisa syndrome (PS) using a combined Magnetic Resonance Imaging (MRI)-, Ultrasonography…
  • 2018 International Congress

    Effects of Botulinum Toxin treatment for sialorrhea in patients with cerebral palsy

    J. Francês Brito, M. Akkari, A. Pinheiro Alves, A. Barbosa de Sousa Junior, B. De Oliveira, O. Vieira Kishi, Jose Roberto Bentes Capeloni (Belem, Brazil)

    Objective: To evaluate the benefits of treatment of drooling with Botulinum Toxin Type A (AbobotulinumtoxinA) in patients with cerebral palsy. Background: Patients with cerebral palsy…
  • 2018 International Congress

    Botulinum toxin A (BoNT A) treatment of postsurgical/posttraumatic focal movements not responding to oral therapy

    A. Lozza, A. Castagna, G. Castelnovo, E. Alfonsi, A. Montini, L. Marchetta, M. Fresia, A. Arrigo, R. Manni (Pavia, Italy)

    Objective: We report three cases of focal movement disorder following trauma or surgery. Oral therapies were ineffective in both patients and symptoms dramatically improved after…
  • 2018 International Congress

    Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series

    C. Wang, E. Wang, H. Lei (Tucson, AZ, USA)

    Objective: To report increased risks of Botulinum Toxin Injection for cervical dystonia and migraine in patients with Hypermobility Ehlers Danlos Syndrome. Background: Ehlers-Danlos syndrome (EDS)…
  • 2018 International Congress

    Botulinum toxin in Restless Leg Syndrome – A Randomized Double-Blind Placebo-Controlled Study

    S. Mittal, D. Machado, D. RIchardson, D. Dubey, B. Jabbari (Bangalore, India)

    Objective: To study the efficacy of incobotulinumtoxin A (IncoA) in relieving the symptoms of restless legs syndrome (RLS) Background: RLS is a common movement disorder…
  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 13
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • #24970 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • An atypical and interesting feature of Parkinson´s disease
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley